<DOC>
	<DOCNO>NCT01504256</DOCNO>
	<brief_summary>The purpose study determine efficacy catumaxomab determination rate macroscopic complete remission peritoneal carcinomatosis treatment one cycle ( four dos ) catumaxomab follow six cycle routine neoadjuvant chemotherapy .</brief_summary>
	<brief_title>Catumaxomab Treatment Peritoneal Carcinomatosis Patients With Gastric Adenocarcinomas</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Antibodies , Bispecific</mesh_term>
	<criteria>Histologically confirm diagnosis resectable gastric adenocarcinoma adenocarcinoma esophagogastric junction ( type II type III accord Siewerts classification ) Macroscopic peritoneal carcinomatosis ( stage P14 accord Gilly et al. , appendix 1 ) Patients potentially eligible gastrectomy primary systemic ( intraperitoneal ) treatment Signed date informed consent start specific protocol procedure Age &gt; 18 year ECOG Performance Status 0 1 Life expectancy least 12 week Adequate bone marrow , liver renal function assess follow laboratory requirement conduct within 7 day prior screen Hemoglobin &gt; 10.0 g/dl Leukocyte count &gt; 4.000/μl ; absolute neutrophil count ( ANC ) &gt; 2.000/μl Platelet count &gt; = 100.000/µl Total bilirubin &lt; 1,5 time upper limit normal ALT AST &lt; 3 x upper limit normal Alkaline phosphatase &lt; 5 x ULN Serum creatinine &lt; 1.5 x upper limit normal creatinine clearance &gt; 60 ml/min The patient willing able comply protocol duration study , include hospital visit treatment schedule followup visit examination Distant metastasis peritoneal seedings Prior diagnosis malignancy cure surgery alone less 5 year study entry Clinically significant cardiovascular disease ( incl . myocardial infarction , unstable angina , symptomatic congestive heart failure , serious uncontrolled cardiac arrhythmia ) = &lt; 1 year enrolment History HIV infection chronic hepatitis B C Active , clinically serious infection ( &gt; grade 2 NCICTC version 3.0 ) Preexisting neuropathy &gt; grade 1 ( NCI CTCAE ) , except loss tendon reflex Patients seizure disorder require medication ( steroids antiepileptic ) History organ allograft Patients undergoing renal dialysis Known hypersensitivity drug give study ; know hypersensitivity murine ( rat and/or mouse ) proteins Any condition unstable could jeopardize safety patient compliance study Excluded therapy medication , previous concomitant : Prior anticancer chemotherapy immunotherapy . Investigational drug therapy outside trial within 4 week study entry Major surgery within 4 week start study , patient must recover effect major surgery Pregnant breastfeeding patient , plan become pregnant within 6 month end treatment . Women childbearing potential must negative pregnancy test perform within 7 day start treatment . Women enrol trial must use adequate barrier birth control measure course trial 6 month end treatment Substance abuse , medical , psychological social condition may interfere patient 's understanding informed consent procedure , participation study evaluation study result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Adenocarcinoma</keyword>
	<keyword>Esophagogastric Junction</keyword>
	<keyword>Peritoneal Carcinomatosis</keyword>
	<keyword>Catumaxomab</keyword>
	<keyword>AIO-STO-0110</keyword>
</DOC>